Atara Biotherapeutics reports early findings of potential efficacy from phase 1 study
Atara Biotherapeutics announced initial efficacy data as well as updated safety results from its ongoing Phase 1 study of ATA188 for treatment of progressive forms of multiple sclerosis. ATA188 is an off-the-shelf, allogeneic T-cell immunotherapy that targets EBV. September 13, 2019